In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia

THE POWER TO PREVENT RISING URIC
ACID LEVELS
IS IN YOUR HANDS

Explore Clinical Data

In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia

THE POWER TO PREVENT RISING URIC ACID LEVELS IS IN YOUR HANDS

Explore Clinical Data

Prevent rising uric acid levels

In a phase 3 trial, ELITEK given prophylactically (prior to anticancer therapy) maintained normal uric acid levels (≤7.5 mg/dL) in significantly more patients (87%, n=92) vs allopurinol (66%, n=91) between 3 and 7 days after initiation of antihyperuricemic treatment (P=0.001) (primary endpoint).1

Mechanism of Action

See how ELITEK functions differently than allopurinol

Identify Patients at Risk

Know what to look for in your patients

Reference: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213.